ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 662,30
-0,58%
Dow Jones
39 112,16
-0,76%
DAX
18 177,62
-0,90%
Brent Oil
84,59
0,48%
Bitcoin
61 748,04
-0,09%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Capricor Therapeutics Inc (CAPR)

  7. Capricor Therapeutics Inc (CAPR) Actualités

CAPR

Capricor Therapeutics (CAPR)

Capricor Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CAPR
DateHeureSourceTitreSymboleSociété
25/06/202416h30GlobeNewswire Inc.CORRECTION: Capricor TherapeuticsNASDAQ:CAPRCapricor Therapeutics Inc
25/06/202414h30GlobeNewswire Inc.Capricor Therapeutics Announces for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
14/06/202422h31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CAPRCapricor Therapeutics Inc
11/06/202415h25GlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA PathwayNASDAQ:CAPRCapricor Therapeutics Inc
04/06/202415h00GlobeNewswire Inc.Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
15/05/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
14/05/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
13/05/202422h05GlobeNewswire Inc.Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
09/05/202415h15GlobeNewswire Inc.Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:CAPRCapricor Therapeutics Inc
08/05/202415h00GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Scientific and Medical ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
06/05/202415h00GlobeNewswire Inc.Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13NASDAQ:CAPRCapricor Therapeutics Inc
24/04/202415h00GlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
21/03/202413h30GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
11/03/202413h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CAPRCapricor Therapeutics Inc
29/02/202422h05GlobeNewswire Inc.Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
27/02/202414h30GlobeNewswire Inc.Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
22/02/202414h30GlobeNewswire Inc.Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29NASDAQ:CAPRCapricor Therapeutics Inc
20/02/202414h30GlobeNewswire Inc.Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward CommercializationNASDAQ:CAPRCapricor Therapeutics Inc
16/02/202423h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CAPRCapricor Therapeutics Inc
24/01/202415h15GlobeNewswire Inc.Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2NASDAQ:CAPRCapricor Therapeutics Inc
04/01/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
17/10/202322h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CAPRCapricor Therapeutics Inc
29/09/202323h02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CAPRCapricor Therapeutics Inc
29/09/202323h00Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:CAPRCapricor Therapeutics Inc
07/09/202300h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
15/06/202323h27Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CAPRCapricor Therapeutics Inc
13/06/202323h21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CAPRCapricor Therapeutics Inc
17/05/202301h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CAPRCapricor Therapeutics Inc
12/05/202315h01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CAPRCapricor Therapeutics Inc
17/04/202323h02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CAPRCapricor Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CAPR

Dernières Valeurs Consultées

EU
ORA
Orange
EU
DG
Vinci
EU
GLE
Societe Generale
USI
USTECH100
US Tech 100
NYSE
KO
Coca Cola
EU
VK
Vallourec
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
EU
AF
Air FranceKLM
EU
EN
Bouygues
EU
VIV
Vivendi
EU
PX1
CAC 40
EU
CS
Axa
EU
PX4
SBF 120
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés